Premium
Samples: to use or not to use?
Author(s) -
Daugherty K. K.
Publication year - 2005
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/j.1365-2710.2005.00691.x
Subject(s) - medical prescription , drug , control (management) , family medicine , business , medicine , pharmacy , public relations , medical education , marketing , nursing , pharmacology , management , political science , economics
Summary The United States Prescription Drug Marketing Act makes people think that samples are simply advertisement for the drug companies. However, this is not the only reason that they are used. Samples make up a large part of most drug companies’ budgets and are used by many clinics with very little control. We need to ensure that these products are being used appropriately. This is becoming a big issue as reports suggest that over 90% of family practise residency clinics allow personal use of drug samples and 60% of pharmaceutical representatives have either used samples for themselves or have given them to non‐physicians. The other disturbing fact is that despite the high use of samples, fewer than 10% of family practise residencies in a Brotzman and Mark study reported having written policies regarding the use of samples. The purpose of this article was to review the literature concerning the reasons for use of drug samples, and the problems associated with such use, and then to discuss possible procedures that offices, especially those that train resident physicians, can implement to ensure good governance, if such use is permitted.